Perry SL - Search Results

1

Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting.

Tiernan JP, Perry SL, Verghese ET, West NP, Yeluri S, Jayne DG, Hughes TA. Tiernan JP, et al. Among authors: perry sl. Br J Cancer. 2013 Feb 19;108(3):662-7. doi: 10.1038/bjc.2012.605. Epub 2013 Jan 15. Br J Cancer. 2013. PMID: 23322207 Free PMC article.

2

CEA-targeted nanoparticles allow specific in vivo fluorescent imaging of colorectal cancer models.

Tiernan JP, Ingram N, Marston G, Perry SL, Rushworth JV, Coletta PL, Millner PA, Jayne DG, Hughes TA. Tiernan JP, et al. Among authors: perry sl. Nanomedicine (Lond). 2015;10(8):1223-31. doi: 10.2217/nnm.14.202. Epub 2015 Feb 19. Nanomedicine (Lond). 2015. PMID: 25694062 Free article.

3

The utility of c-Met as a diagnostic tissue biomarker in primary colorectal cancer.

Armstrong GR, Khot MI, Tiernan JP, West NP, Perry SL, Maisey TI, Hughes TA, Jayne DG. Armstrong GR, et al. Among authors: perry sl. Int J Exp Pathol. 2021 Jun;102(3):172-178. doi: 10.1111/iep.12395. Epub 2021 May 5. Int J Exp Pathol. 2021. PMID: 33951261 Free PMC article.

4

Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells.

Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG. Madhok BM, et al. Among authors: perry sl. Br J Cancer. 2010 Jun 8;102(12):1746-52. doi: 10.1038/sj.bjc.6605701. Epub 2010 May 18. Br J Cancer. 2010. PMID: 20485289 Free PMC article.

5

A novel fluorescent c-met targeted imaging agent for intra-operative colonic tumour mapping: Translation from the laboratory into a clinical trial.

Armstrong GR, Khot MI, Portal C, West NP, Perry SL, Maisey TI, Tiernan JP, Hughes TA, Tolan DJ, Jayne DG. Armstrong GR, et al. Among authors: perry sl. Surg Oncol. 2022 Mar;40:101679. doi: 10.1016/j.suronc.2021.101679. Epub 2021 Nov 20. Surg Oncol. 2022. PMID: 34839199 Clinical Trial.

6

Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker.

Zougman A, Hutchins GG, Cairns DA, Verghese E, Perry SL, Jayne DG, Selby PJ, Banks RE. Zougman A, et al. Among authors: perry sl. Eur J Cancer. 2013 Jan;49(2):531-9. doi: 10.1016/j.ejca.2012.07.031. Epub 2012 Sep 26. Eur J Cancer. 2013. PMID: 23021913

7

Activated mesothelial cells produce heparin-binding growth factors: implications for tumour metastases.

Jayne DG, Perry SL, Morrison E, Farmery SM, Guillou PJ. Jayne DG, et al. Among authors: perry sl. Br J Cancer. 2000 Mar;82(6):1233-8. doi: 10.1054/bjoc.1999.1068. Br J Cancer. 2000. PMID: 10735511 Free PMC article.

8

Expression of cyclin D2 is an independent predictor of the development of hepatic metastasis in colorectal cancer.

Sarkar R, Hunter IA, Rajaganeshan R, Perry SL, Guillou P, Jayne DG. Sarkar R, et al. Among authors: perry sl. Colorectal Dis. 2010 Apr;12(4):316-23. doi: 10.1111/j.1463-1318.2009.01829.x. Epub 2009 Mar 11. Colorectal Dis. 2010. PMID: 19508551

9

Inhibiting ABCG2 could potentially enhance the efficacy of hypericin-mediated photodynamic therapy in spheroidal cell models of colorectal cancer.

Khot MI, Perry SL, Maisey T, Armstrong G, Andrew H, Hughes TA, Kapur N, Jayne DG. Khot MI, et al. Among authors: perry sl. Photodiagnosis Photodyn Ther. 2018 Sep;23:221-229. doi: 10.1016/j.pdpdt.2018.06.027. Epub 2018 Jun 30. Photodiagnosis Photodyn Ther. 2018. PMID: 29969677 Free article.

10

Targeting glucose metabolism: an emerging concept for anticancer therapy.

Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG. Madhok BM, et al. Among authors: perry sl. Am J Clin Oncol. 2011 Dec;34(6):628-35. doi: 10.1097/COC.0b013e3181e84dec. Am J Clin Oncol. 2011. PMID: 20805739 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

138 results

Search Page

Filters